TY  - JOUR
AU  - Chi, Kim N
AU  - Agarwal, Neeraj
AU  - Bjartell, Anders
AU  - Chung, Byung Ha
AU  - Pereira de Santana Gomes, Andrea J
AU  - Given, Robert
AU  - Juárez Soto, Álvaro
AU  - Merseburger, Axel S
AU  - Özgüroğlu, Mustafa
AU  - Uemura, Hirotsugu
AU  - Ye, Dingwei
AU  - Deprince, Kris
AU  - Naini, Vahid
AU  - Li, Jinhui
AU  - Cheng, Shinta
AU  - Yu, Margaret K
AU  - Zhang, Ke
AU  - Larsen, Julie S
AU  - McCarthy, Sharon
AU  - Chowdhury, Simon
AU  - TITAN Investigators
PY  - 2019
DO  - 10.1056/NEJMoa1903307
UR  - http://hdl.handle.net/10668/14047
T2  - The New England journal of medicine
AB  - Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression-free survival and overall survival as compared with...
LA  - en
KW  - Adenocarcinoma
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Androgen Antagonists
KW  - Androgen Receptor Antagonists
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Double-Blind Method
KW  - Exanthema
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Grading
KW  - Progression-Free Survival
KW  - Prostatic Neoplasms
KW  - Quality of Life
KW  - Radiography
KW  - Thiohydantoins
TI  - Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
TY  - research article
VL  - 381
ER  -